

**Remarks**

Applicants have cancelled claims 1- 60 without prejudice to their rights to pursue the subject matter of these claims in other applications. Applicants have added new claims 61 to 69 which more clearly define the subject matter of the invention and properly fall within the subject matter of the elected group I claims.

Claims 61- 69 are pending. Support for the newly added claims is found through the specification and in the originally filed claims. In particular, support for the gene BTG family, member 2 (BTG2) is noted in Table Y under the RNA accession number NM\_006763.1 with a p value of 0.007557581 and is described in Figure 26, Example 27. BTG2 is also noted in Table 3AC with a p value of 0.001315072 and is further described in Example 51. No new matter has been added.

In response to the Restriction Requirement dated September 1, 2006, Applicants elect **Group I** and claims drawn to a method of detecting schizophrenia.

The restriction requirement states that a further election is required if Group I claims are elected of a single combination of "one or more" markers from Tables 3Y and 3AC for detection in the claimed methods. As noted, the Applicant has elected the selection of the biomarker BTG family, member 2 (BTG2) which is found in both Table Y and Table 3AC.

A petition for extension of time is attached. However, should any fees be required to ensure consideration of this response, the Commissioner is authorized to charge Deposit Account 04-1105, Reference No. 204231/2055P.

Respectfully submitted,

Date: January 3, 2007

*Amy DeCloux*

*Amy DeCloux*  
*54849*

Name: Kathleen M. Williams

Registration No.: 34,380

Customer No.: 29933

Edwards Angell Palmer & Dodge LLP

P.O. Box 55874

Boston, MA 02205

Tel: 617-239-0100